玻璃体腔注射Avastin治疗病理性近视黄斑CNV的临床观察被引量：2

Clinical observation on pathologic myopia CNV treated with intravitreal bevacizumab

下载PDF

导出

摘要目的:观察病理性近视(pathologic myopia,PM)黄斑脉络膜新生血管(choroidal neovascularization,CNV)经Avastin治疗后眼部病变和最佳矫正视力(best corrected visual acuity,BCVA)变化,结合光相干断层扫描(optical coherence tomography,OCT),荧光素眼底血管造影(fluorescence fundus angiography,FFA)的结果,评价Avastin治疗PM黄斑CNV的临床疗效和安全性。方法:PM黄斑CNV41例42眼,随机分为两组,试验组21例22眼采用玻璃体腔注射Avastin联合口服复方血栓通胶囊治疗;对照组20例20眼仅口服复方血栓通胶囊治疗,剂量、疗程同实验组。两组随访时间均为12mo,统计分析两组BCVA、眼底检查、FFA及OCT检查结果,评价Avastin治疗PM黄斑CNV的临床疗效和安全性。结果:BVCA:试验组平均提高4.23±2.02行,对照组平均提高1.95±1.90行,组间差异有统计学意义(P<0.005),试验组提高较对照组明显;OCT:比较两组中央视网膜厚度(central foveal thickness,CFT),试验组和对照组减低平均值分别是43.41±40.39和22.65±20.79μm,组间差异有统计学意义(P<0.05),实验组CFT减低程度较对照组明显;FFA:治疗后试验组20眼(91%)渗漏消失,2眼(9%)渗漏持续存在;对照组12眼(60%)完全消失,8眼(40%)持续存在,组间差异有统计学意义(P<0.05),实验组渗漏明显减轻。结论:Avastin可有效减轻病理性近视CNV的渗漏,缩短病程,提高视力,治疗安全。 AIM： To evaluate the efficacy and safety of intravitreal bevacizumab （Avastin） for choroidal neovascularization （CNV） in pathologic myopia （PM） by including optical coherence tomography （ OCT）, fluorescein angiography （FFA） and best-corrected visual acuity（BCVA）. METHODS： Totally 42 eyes in 41 patients with PM CNV were divided into 2 groups randomly, experimental group （n = 22 ） were assigned to receive intravitreal bevacizumab injections and take fufangxueshuantong capsule; contro group （ n = 20 ） just took fufangxueshuantong capsule. Subjects were followed up every month after treatment. The efficacy and safety of two group were compared by ophthalmic evaluations including OCT, FFA, and BCVA. RESULTS： BCVA： BCVA in two groups was improved after 12 months. The mean number of treatments per eye, experimental group was 4. 23± 2. 02 and control group was 1.95±1.90. There was significant difference（ P〈 0. 005）. OCT： Before and after 12 months central foveal thickness（CFD） for two groups were thin,and the meanvalue in experimental group was 43.41 ±40. 39μm and in control group was 22.65±20. 79μm, there was significant difference（ P〈 0.05） ; FFA： In experimental group CNV was completely disappeared in 20 eyes （91%）, persistent in 2 eyes（9%）; the control group CNV was completely disappeared in 12 eyes （60%）, persistent in 8 eyes （40%）. There was significant difference（P〈0.05）. CONCLUSION： Intravitreal bevacizumab are safe and effective treatment for most patients of CNV in PM.

作者刘政群朱小华岳辉

机构地区中国湖南省长沙市第四医院眼科中南大学湘雅二医院眼科

出处《国际眼科杂志》 CAS 2013年第5期953-956,共4页 International Eye Science

关键词病理性近视脉络膜新生血管血管内皮生长因子 AVASTIN vascular endothelium growth factor pathological myopia choroidal nevascularization Avastin

分类号 R778.11 [医药卫生—眼科]

引文网络
相关文献

参考文献15

1许薇琦,Philip J Rosenfeld,孙晓东.病理性近视脉络膜新生血管的治疗[J].上海交通大学学报（医学版）,2008,28(6):731-735. 被引量：11
2于志强,褚仁远,等.病理性近视眼脉络膜新生血管膜临床研究进展[J].中国眼耳鼻喉科杂志,2002,2(1):53-56. 被引量：4
3李凤呜.中华眼科学.北京:人民卫生出版社:2004:1920-192l.
4Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retial disorders. N Engl J Med1994 ;331 ( 22 ) : 1480-1487.
5Tong JP, Chan WM, Liu DT, et al . Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization.Am J Ophthalmol 2006 ; 141 ( 3 ) :456-462.
6Adamis AP, Miller JW, Bernal MT, et al . Increased vascular endothelial growth factor levels in the vitreous of eyes with prolifeative diabetic retinopathy. Am J Ophthalmol 1994 ; 118 (4) :445-450.
7Cohen AF, Van Bronswjk H. New medications : bevacizumab. Ned Tijdschr Geneeskd 2006 ; 150(40 ) :2194-2195.
8Fung AE, Rosenfeld PJ, Reichel E. The international intravitreal bevacizumab, safety survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 2006 ;90 ( 11 ) : 1344-1349.
9Chan WM, Lai TY, Liu DT, et al . Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study. Ophthalmology 2007 ; 114 ( 12 ) : 2190- 2196.
10Gharbiya M, Allievi F, Mazzeo L, et al. Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12- month results. Am J Ophthalmol 2009;147 (1) :84-93.

二级参考文献61

1Mainster MA.Wavelength selection in maeular photocoagulation. Ophthalmol, 1986,93 : 952.
2L' esperance FA.Clinical applications of the organic dye laser.Ophthalmol 1985,92:1592.
3Brancato R.Pece A.Avanza P.et al.Laser treatment of subretinal macular neovascularization in pathological myopia.J Fr Ophtalmol, 1989.12(12) :883.
4Braneato R,Menchini U,Pece A,et al. Dye laser photocoagulation of maeula subretinal neovascularization in pathological myopia.Int Ophthalmol,1988,11:235.
5Morgan CM.Howard S.Atrophic creep of the retinal pigment epithelium after focal macular photocoagulation.Ophthalmol 1989,96:96.
6Grabowski WM.Decker WL.Annesley WH.et al.Complications of Krypton red laser photocoagulation to subretinal neovascular membranes.Ophthalmol 1984,91 : 1587.
7Robert J.Howard S.Delayed choroidal vascular filling after krypton laser photocagulation.Am J Ophtholmol 1985,99:154.
8Caskey PJ.Folk JC.Retinal revascularization following laser photocoagulation treatment for choroidal neovascular membranes. Arch Ophthalmol, 1958,106:1528.
9Pece A.Serini P.Avanza.P.et al.Degenerative myopia:recurrence of subretinal neovessels after laser photocoagulation.J Fr Ophtalmol 1990,13 : 24.
10Brancato R.Pece A.Avanza P.et al.Photocagulation scar expansion after laser therapy for choroidal neovascularization in degenerative myopia Retina, 1990,10: 239.